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trial with a GM maize MON810 variety, its near-isogenic 
non-GM comparator and an additional conventional maize 
variety are presented. The feeding trials were performed 
by taking into account the guidance for such studies pub-
lished by the EFSA Scientific Committee in 2011 and the 
OECD Test Guideline 452. The results obtained show that 
the MON810 maize at a level of up to 33 % in the diet did 
not induce adverse effects in male and female Wistar Han 
RCC rats after a chronic exposure.
Abstract The GRACE (GMO Risk Assessment and Com-
munication of Evidence; www.grace-fp7.eu) project was 
funded by the European Commission within the 7th Frame-
work Programme. A key objective of GRACE was to con-
duct 90-day animal feeding trials, animal studies with an 
extended time frame as well as analytical, in vitro and in 
silico studies on genetically modified (GM) maize in order 
to comparatively evaluate their use in GM plant risk assess-
ment. In the present study, the results of a 1-year feeding 
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Introduction
The GRACE (GMO Risk Assessment and Communication 
of Evidence; www.grace-fp7.eu) project is a collaborative 
project, which involved 19 partners from 13 different Euro-
pean countries and was funded by the European Commis-
sion within the 7th Framework Programme between July 
2012 and November 2015. A key objective of GRACE 
was to test GM maize MON810 varieties in subchronic 
and chronic animal feeding trials and alternative in vitro 
methods in order to determine how suitable the above-
mentioned test systems are and whether they provide useful 
scientific information for the health risk assessment of GM 
food and feed in an “untargeted approach”, i.e. without a 
triggering indication of potential effects.
In the present study, the results of a 1-year feeding trial 
with a GM maize MON810 variety, its near-isogenic non-
GM comparator and an additional conventional maize 
variety are presented. The transgenic trait MON810 con-
sists of a Bacillus thuringiensis (Bt)-derived gene, namely 
a truncated cry1Ab gene encoding an insecticidal protein 
(δ-endotoxin) (Schnepf et al. 1998), for the control of 
some lepidopteran insect pests such as the European corn 
borer (Ostrinia nubilalis) (Hill et al. 1995). The selected 
MON810 variety was one of the most widely used by 
farmers in Catalonia, Spain. In the 1-year feeding trial, not 
only the corresponding near-isogenic non-GM maize com-
parator but also a conventional maize variety was tested, 
since the Slovak Medical University (Bratislava, Slova-
kia), the institution conducting the feeding trials, had not 
performed such an extended study with maize in the past 
and, therefore, appropriate historical data with which one 
could compare the results obtained in the present study 
were lacking.
The study design was derived from the OECD Test 
Guideline 452 for Testing of Chemicals–Chronic toxic-
ity studies (OECD TG 452; OECD 2009) and took into 
account recommendations of the European Food Safety 
Authority (EFSA) when wanting to analyse the poten-
tial subchronic toxicity of whole food and feed in rodents 
(EFSA Scientific Committee 2011). The composition of 
the feed was analysed, the body weight and the feed con-
sumption were monitored, clinical and ophthalmologi-
cal observations were recorded, haematology and clini-
cal biochemistry parameters were quantified, and a gross 
necropsy including the determination of the absolute and 




Maize was produced in Pla de Foixà (Girona, Catalonia, 
Spain, 42°05′N, 3°E) during the growing season of 2013. 
This area is close to the sea and has a Mediterranean cli-
mate. The soil type is Xerofluven oxiaquic, coarse-loamy, 
mixed, calcareous and thermic. Three varieties were pro-
duced, all commercially cultivated in that region: a GM 
maize MON810 and its near-isogenic non-GM compara-
tor as well as an additional conventional variety (Table 1). 
The seeds were purchased at the local market. About 1.5 ha 
of each variety was sown. There was no maize cultured 
in neighbouring fields that had been sown at the same 
period of time, so that the probability of cross-pollination 
was minimized. Maize was cultivated following standard 
agricultural practices in the area, including N, P and K 
fertilization (up to 300, 100 and 175 kg/ha, respectively). 
Weeds were controlled by pre-emergence application of 
4 L HARNESS® GTZ per ha (41 % Acetochlor + 19.5 % 
Terbuthylazine) and by post-emergence application of 0.6 
L ELITE PLUS per ha (4 % nicosulfuron) and 1 L Cal-
listo® per ha (480 g/L mesotrione) or MUSTANG (30 % 
2,4-D and 0.6 % florasulam), if needed. No insecticide was 
applied. In-furrow irrigations were supplied when needed 
during the cropping season. Maize was planted at a density 
of 80,000 plants ha−1 with 75-cm row spacing and 14-cm 
seed spacing.
Agronomic, morphologic, phenological and health 
parameters were monitored and were as usual in the region. 
Specifically, Sesamia nonagrioides and Ostrinia nubi-
lalis infestations were not detected in the near-isogenic 
(DKC6666) and the GM (DKC6667-YG) maize, but 3.3 % 
Table 1  Maize variety content of the different diets used in the 
1-year rat feeding trial
a Near-isogenic maize variety of DKC6667-YG, from Monsanto
b Transgenic maize variety (MON810), from Monsanto
c Conventional maize variety, from Koipesol Semillas
Diet Maize variety content (%)
33 % near-isogenic non-GM 
maize
33 % DKC6666a
11 % MON810 11 % DKC6667-YGb + 22 % 
DKC6666
33 % MON810 33 % DKC6667-YG
33 % conventional 2 33 % SY NEPALc
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of SY-NEPAL plants were infested. There was some fun-
gal infection in non-GM plants, and Fusarium spp. was 
detected in 2.5 and 1.3 % of DKC6666 and SY-NEPAL 
stalks, respectively. There was no relevant viral infection. A 
good yield (i.e. 12,000–13,000 kg/ha) was achieved. Mete-
orological data were recorded (Electronic Supplementary 
Material, Fig. 1). The central part of each plot was inde-
pendently harvested, and kernels were removed from the 
cobs on-site by machine. They had grain moisture levels in 
the usual range and were dried in a biological dryer, kept 
below 60 °C, down to a moisture level of 13–14 %.
Diet preparation and analyses
Two tons of DKC6666 maize, two tons of DKC6667-YG 
maize and one ton of SY-NEPAL maize were transported to 
Mucedola srl (Milan, Italy). The kernels were then milled 
(mesh size: 1 mm), coded and used to prepare the feed. The 
formulation of the diets was standard for all trials of the 
project (Zeljenková et al. 2014) except for the maize varie-
ties used. It was isoproteic, isocaloric and adjusted to the 
dietary requirements of the rat strain Wistar Han RCC used 
in the feeding trials. Besides the milled maize, the formu-
lation mainly consisted of other plant-derived ingredients, 
including wheat, wheat middlings, soybean meal and soy 
oil, while it did not contain animal-derived ingredients. 
Four different diets in pellet form (Table 1) were prepared 
in two batches, whereby the resulting pellets were dried at 
a temperature <50 °C, coded in a blinded fashion and sent 
to the Slovak Medical University (Bratislava, Slovakia) for 
the feeding trials as vacuum-packed, γ-irradiated batches 
(irradiation dose = 25 kGy).
Both batches of all four diets were analysed. Before dis-
patched to RIKILT Wageningen UR (Wageningen Univer-
sity and Research Centre, Wageningen, The Netherlands), 
small maize and diet subsamples were retained at the ani-
mal feed producing facility (Mucedola srl) for analysis. 
Diet samples of 1.5 kg each were sent to RIKILT Wagenin-
gen UR, where the feed pellets were milled and re-mixed. 
Thereafter, subsamples were dispatched to Covance (Madi-
son, WI, USA). A list of the parameters measured, the ana-
lytical methods used and the institutions that performed the 
individual analyses is shown in Table 1 of the Electronic 
Supplementary Material. The feed analyses were per-
formed in certified laboratories.
Study design
The sample size of 20 rats per group, as described in the 
OECD TG 452 (OECD 2009), was chosen. A power analy-
sis revealed that this group size would have a 85 % chance 
of detecting a standardized effect size (SES: the difference 
in means between control and treated groups divided by the 
standard deviation [SD]) of 1.0 SD by assuming the cage 
with two rats to be the experimental unit, at a 5 % signifi-
cance level and by performing a two-sided test to compare 
the effects of the control and GMO diets in rats.
The total number of animals was 160, with 20 animals 
(10 cages) per gender and dietary treatment. Three dietary 
treatments represent the groups “control”, “11 % GMO” 
and “33 % GMO”. An additional group being fed a conven-
tional maize variety with the same sample size per gender 
and group was included. Consequently, the factor “group” 
has four levels, namely “control”, “11 % GMO”, “33 % 
GMO” and “conventional 2”.1
Experimental unit
As recommended by EFSA (EFSA Scientific Committee 
2011), two animals of the same gender were housed per 
cage and the cage was taken as the experimental unit.
Rat feeding trial
The rat feeding trial was conducted by taking into account 
the OECD TG 452 (OECD 2009) and recommendations 
included in the EFSA Guidance on conducting repeated-
dose 90-day oral toxicity study in rodents on whole food/
feed (EFSA Scientific Committee 2011). The trials were 
performed in compliance with GLP in the experimen-
tal animal house at the Department of Toxicology of the 
Slovak Medical University in Bratislava (Slovakia). Five-
week old male and female Wistar Han RCC rats were pur-
chased from Harlan (San Pietro al Natisone, Italy), and the 
study was started 1 week after delivery of the animals at 
the animal testing facility (i.e. in January 2014). Twenty 
animals with a uniform weight (±3–5 % of the mean) per 
group were used, two animals were placed in one cage 
(=experimental unit), and each animal was allocated to the 
individual cages by dose group and sex in such a way that 
the average weight between the treatment groups was sim-
ilar. The feeding trial was started as follows: (1) feeding 
start for males on day 1 and (2) feeding start for females 
1 day later. A detailed examination of all animals to verify 
their health condition (see “Periodical health status obser-
vations” section) was carried out just before the start of the 
feeding trials. Feed and water were supplied ad libitum. 
Feed consumption was determined once weekly during the 
first 13 weeks, every 2 weeks thereafter, and reported as 
the total amount of feed consumed by two animals in one 
cage per week or 2 weeks, respectively.
1 The “conventional 2” group is named like that, since it refers to 
the same “conventional 2” variety (SY-NEPAL) tested in the 90-day 
feeding trial A previously described by Zeljenková et al. (2014).
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As mentioned before, two batches of each individual 
diet were produced. In the case of the male rats, the 2nd 
batch of the 33 % GMO and conventional 2 diets was fed 
from week 34 onwards, while the 2nd batch of the control 
and 11 % GMO diets was fed from week 33 onwards. In 
the case of the female rats, the 2nd batch of the control and 
33 % GMO diets was fed from week 34 onwards, while the 
2nd batch of the 11 % GMO and conventional 2 diets was 
fed from week 33 onwards.
Periodical health status observations
Rats were inspected twice daily for changes in skin, fur, 
eyes, mucous membranes, occurrence of secretions and 
excretions as well as activity level and change in behaviour. 
A detailed physical examination of each animal out of the 
cage was performed prior to the beginning of the feeding 
trial, on day 1, once weekly during the first 13 weeks and 
once monthly thereafter to identify changes in skin, fur, 
eyes, mucous membranes, occurrence of secretions and 
excretions, and autonomic activity such as lacrimation, 
piloerection, pupil size, unusual respiratory patterns as well 
as activity level and change in behaviour. At the end of the 
feeding trials, a functional assessment of changes in gait, 
posture and response to handling as well as the presence 
of clonic or tonic movements or bizarre behaviour (self-
mutilation, walking backwards) was carried out. Sensory 
reactivity to auditory, visual and proprioceptive stimuli was 
recorded. An ophthalmologic examination of both eyes of 
all animals in the conscious state was performed prior to 
the beginning of the feeding trial and 2 weeks before the 
end of the study. The eyes and the peribulbar structures 
were examined macroscopically after pupillary dilatation 
induced by instillation of a 0.5 % tropicamide solution. 
Each animal was weighed 48 h after its arrival at the exper-
imental animal house of the Slovak Medical University, on 
the randomization day (i.e. one day before the beginning of 
the feeding trial), on the first day of the feeding trial, once 
weekly during the first 13 weeks, once every 2 weeks there-
after and at the end of the study.
Haematology and clinical biochemistry analyses
At the end of months 3 and 6, blood samples from the tail 
vein of 10 males and 10 females per group after 16–18 h 
fasting were taken for the haematological analyses (with 
EDTA as anticoagulant) as well as for the clinical biochem-
istry analyses (without anticoagulant), thereby making 
use of the same animals at both points in time. At month 
12, samples were taken from all animals in the 4 groups 
after 16–18 h fasting for the haematological analyses (with 
EDTA as anticoagulant) as well as for the clinical biochem-
istry analyses (without anticoagulant).
The order in which blood samples were taken for the 
haematology analyses is shown in Table 2 of the Electronic 
Supplementary Material. No later than four hours after col-
lection of the blood samples, the following haematology 
parameters were measured by making use of a Sysmex 
K-4500 automated haematology analyser (Sysmex, Kobe, 
Japan): white blood cell count (WBC), red blood cell count 
(RBC), haemoglobin concentration (HGB), haematocrit 
(HCT), mean cell volume (MCV), mean corpuscular hae-
moglobin (MCH), mean corpuscular haemoglobin con-
centration (MCHC), platelet count (PLT) and lymphocyte 
count (LYM). For the differential leucocyte count, blood 
smears were stained with the May–Grunwald and Giemsa–
Romanowski dyes and thereafter examined by light 
microscopy; the percentage of lymphocytes, neutrophils, 
eosinophils, basophils and monocytes were determined by 
examining 200 cells.
The order in which blood samples were taken for the 
biochemistry analyses is also shown in Table 2 of the Elec-
tronic Supplementary Material. The parameters alkaline 
phosphatase (ALP), alanine aminotransferase (ALT), aspar-
tate aminotransferase (AST), albumin (ALB), total protein 
(TP), glucose (GLU), creatinine (CREA), urea (U), choles-
terol (CHOL), triglycerides (TRG), calcium (Ca), chloride 
(Cl), potassium (K), sodium (Na) and phosphorus (P) were 
measured maximally 4 h after collection of the blood sam-
ples in serum with an Ortho Clinical Vitros® 250 Chemis-
try System (Ortho-Clinical Diagnostics, Raritan, NJ, USA), 
whereas coagulation parameters were not determined.
Urinalysis
An analysis of urine was performed at months 3, 6 and 
12 on 10 male and 10 female rats using the same animals 
throughout. Urine was collected from each individual rat in 
metabolic cages for 16 h. The parameters total protein, glu-
cose, ketone, leucocyte number, erythrocyte number, biliru-
bin, urobilinogen, nitrate and pH were analysed with Com-
bur10Test® UX test strips (Roche Diagnostics, Mannheim, 
Germany) and semi-quantitatively evaluated by reflectance 
photometry with a Urilux S analyser (Roche Diagnostics). 
Osmolality was measured with the Advanced® Model 3300 
micro-osmometer from Advanced Instruments (Norwood, 
MA, USA).
Gross necropsy and histopathology
At the end of the study, rats were anaesthetized after a 
16- to 18-h fasting period with 10 mg/kg bw xylazine and 
75 mg/kg bw ketamine. The order in which necropsy was 
performed is also shown in Table 2 of the Electronic Sup-
plementary Material. Blood samples were taken from the 
abdominal aorta and in four cases from the inferior vena 
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cava for possible omics analyses being outside the scope 
of this publication. Thereafter, the successive necropsy 
of the thoracic cavity, the abdominal cavity, the genital 
organs and, following decapitation, the head was per-
formed. Moreover, the wet weight of the kidneys, spleen, 
liver, adrenal glands, lung, heart, thymus, pancreas, uterus, 
ovaries, testes, epididymides and brain of all animals was 
recorded. Organ samples were stored in neutrally buffered 
10 % formalin, except for the eyes and the male reproduc-
tive tissues, which were immersed in Bouin’s solution, and 
sent to TOPALAB (Košice, Slovakia) for their histopatho-
logical examination.
A complete microscopic examination of the brain 
(including cerebrum, cerebellum and medulla/pons), spi-
nal cord (at the cervical, mid-thoracic and lumbar level), 
pituitary, thyroid, parathyroid, thymus, oesophagus, sali-
vary glands, stomach, small and large intestines, liver, pan-
creas, kidneys, adrenals, spleen, heart, trachea and lungs 
(preserved by inflation with fixative and then immersion), 
aorta, gonads, uterus, female mammary gland, prostate, 
urinary bladder, lymph nodes, peripheral nerve, bone mar-
row and skin from all animals in the control and high dose 
groups was performed. In order to do so, the formalin-fixed 
tissue samples were washed, dehydrated and embedded in 
paraffin. Thereafter, 4-µm-thick sections were stained with 
haematoxylin and eosin for the light microscopic examina-
tion of the tissue structure. All tissues from animals killed 
before the end of the study (animal Nos. 15, 131 and 159), 
and all tissues from animals fed the conventional 2 and 
11 % GMO diets showing macroscopic alterations were 
also examined (see Electronic Supplementary Material 
Tables 8 and 9).
Statistics
The raw data of the trial were collated in Excel files. Data 
were screened for their structure, and data and variable def-
initions were settled (Appendix 1 in Schmidt et al. 2015a). 
Based on these definitions, a SAS analysis data set was cre-
ated by using SAS Software version 9.4 (SAS Institute Inc., 
Cary, NC). Mean values per cage were calculated for all 
endpoints except for feed consumption. The feed efficiency 
per week until week 13 and per 2 weeks thereafter (weight 
gain [g]/feed intake [g] × 100) and the relative organ 
weights (organ weight [g]/body weight [g] × 100) were 
computed. Data were screened for outliers and extreme val-
ues (Appendix 2 in Schmidt et al. 2015a). For each gen-
der–group, factor level combination and all variables, box-
and-whisker plots were created to identify extreme values 
(variable values outside 1.5* interquartile range). Extreme 
values were marked in the Excel sheet of original data for 
easier identification of irregular patterns or suspicious ani-
mals. Growth curves of all animals were plotted (scatter 
plots, weight against study day) and visually inspected for 
irregular patterns (Appendix 2 in Schmidt et al. 2015a). 
To describe the data, summary statistics including means, 
standard deviations, 95 % confidence intervals, medians, 
number of valid values, minima and maxima were calcu-
lated and tabulated. Additionally to the box-and-whisker 
plots, plots of means and 95 % confidence intervals were 
drawn. Descriptive analysis was performed separately for 
each gender and group and on an animal basis (Appendix 3 
in Schmidt et al. 2015a).
The body weight, feed consumption and feed efficiency 
data (per cage) were analysed by applying mixed models 
and by using the restricted maximum likelihood (REML) 
algorithm with AR covariance structure, combined and 
separately for male and female animals. The group (four 
levels) was considered a fixed factor. The factor week 
(time in weeks from the start of the experiment) was con-
sidered a continuous fixed factor (Appendix 4 in Schmidt 
et al. 2015a). For least square mean body weights and for 
all other endpoints, SES and their 95 % confidence inter-
vals were calculated for each observation date (i.e. 3, 6 
and 12 months) according to Nakagawa and Cuthill (2007; 
for details, see Schmidt et al. 2015b). The GMO and the 
conventional 2 groups were compared to the control group 
(three comparisons: 11 % GMO–control, 33 % GMO–con-
trol and conventional 2–control) (Appendix 5 in Schmidt 
et al. 2015a). The SES estimates are displayed as graphs 
displaying both statistical significance and the ±1.0 SD 
interval (as assumed in the sample size calculation based on 
an EFSA guidance document [EFSA Scientific Committee 
2011]) for each of the endpoint comparison results (Fig. 1). 
All endpoints are shown on the same graph (separately for 
the male and female rats), thereby forming an overall pat-
tern and allowing the assessment of group comparisons 
at a glance. In addition, in order to compare the temporal 
courses of the haematology and clinical biochemistry end-
points (per cage), mixed models and the restricted maxi-
mum likelihood (REML) algorithm with AR covariance 
structure were applied. The group (four levels) was consid-
ered a fixed factor. The factor time (observation points in 
time at 3, 6 and 12 months) was considered a continuous 
fixed factor (Appendix 6 in Schmidt et al. 2015a).
A “classical” statistical analysis was also performed. In 
a first step, the generic assumptions underlying the ANOVA 
post hoc tests were checked: for the normality of the data, 
Kolmogorov–Smirnov (with Lilliefors correction) tests 
were performed. For residuals, scaled-by-predicted plots, 
residual histograms and residual QQ plots were gener-
ated (Appendix 7 in Schmidt et al. 2015a). For variance 
homogeneity, Levene’s test was performed. Based on this 
test and following a decision tree (OECD 2012; Schmidt 
et al. 2015b), the appropriate test procedure was chosen 
(Appendix 10 in Schmidt et al. 2015a): an ANOVA with 
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post hoc Dunnett test was applied in the case of quantita-
tive data being independent observations with normally 
distributed residuals and equal variances in the groups. For 
qualitative data and quantitative data, in which the ANOVA 
assumptions were not met, the Kruskal–Wallis followed by 
the Wilcoxon test was applied. Group means and standard 
deviations (data per cage) of all endpoints were listed in 
form of tables (Appendix 8 in Schmidt et al. 2015a). The 
significances obtained with the above-mentioned decision 
tree-based “classical” statistical analysis procedure as well 
as the significances identified by SES confidence intervals 
are shown in Tables 4, 5 and 8 listing the haematology, 
clinical biochemistry and relative organ weight data of the 
feeding trial, respectively.
To illustrate and compare the consequences of applying 
several parametric and nonparametric methods, all end-
points were analysed by three commonly used tests, namely 
an ANOVA followed by both the t and the Dunnett test as 
well as the Kruskal–Wallis test followed by the Wilcoxon 
test. The resulting significances were compared to each 
other and to the significances identified by SES confidence 
intervals (Appendices 9 and 10 in Schmidt et al. 2015a).
In this paper, when comparing haematology and clinical 
biochemistry parameters as well as relative organ weights 
between a control and a second group, the wording “signif-
icantly different” is based on the interpretation of the calcu-
lated SES estimates (Fig. 1). Furthermore, in those cases, 
in which the classical statistical analysis methods revealed 
differences between the control group and the 11 % GMO 
and/or 33 % GMO group not identified by the SES confi-
dence intervals, these are mentioned in “Results” section.
Stakeholder consultations
A key characteristic of the GRACE project is to allow for 
a broad involvement of stakeholders and to ensure utmost 
transparency of the research process. The main stakeholder 
groups targeted were competent authorities, industry, civil 
society organizations, and researchers interested or expe-
rienced in animal feeding studies with GM food/feed. The 
groups contacted were much broader and also included, 
for example, agricultural, professional and international 
organizations.
A draft study plan was sent per e-mail to 738 stakehold-
ers. A total of 122 comments were received from eight indi-
viduals or organizations. These comments were discussed 
by the study team and taken into account when finalizing 
the study plan. Study team members answered in a written 
form the stakeholder comments, thereby allowing them to 
track if and how their comments were taken into consid-
eration and to understand the underlying reasons for taking 
them into account or not.
In a similar way, the draft results, interpretations and 
conclusions were subjected to stakeholder scrutiny in the 
course of the final round of stakeholder consultations on 
GRACE results. More than 1300 stakeholders were con-
tacted, 27 participated in a workshop held in October 2015, 
and 6 of the workshop participants provided additional 41 
comments in writing. In order to facilitate this process, 
draft documents and raw data were made available to reg-
istered participants that had agreed to sign a non-disclosure 
agreement. Again, all comments were considered when 
completing interpretation and conclusions, and written 
responses were prepared by the study team.
All comments and the written responses of the study 
team members were documented in consultation reports 
and published at the project website alongside with the 
draft and revised study plan (http://www.grace-fp7.eu). 
Stakeholder participation was not selected in any way: 
all interested stakeholder representatives could partici-
pate. In each consultation step, representatives of all main 




A detailed quantitative analysis of the different components 
of the diets used in the feeding trial was performed; the 
Fig. 1  Simplified version of a graph allowing visual assessment of 
statistical significance as well as the supposed biological and possi-
ble toxicological relevance of group comparisons. The standard effect 
size point estimate (circle) and the 95 % confidence limits (whiskers, 
bars show confidence interval) illustrate the (standardized) effect size 
between two groups. The vertical black line indicates no effect (zero 
difference), while the vertical grey lines indicate the supposed bio-
logical and possible toxicological relevance limits (here ±1.0 SD, 
according to the study design). If the confidence interval bars cross 
the zero line but not the grey lines (lie within the ±1.0 limits), there 
is evidence for no statistical significance as well as no biological rel-
evance (case a). Two groups are significantly different when the con-
fidence interval bars do not cross the black vertical line (cases b, c). 
The effect size between two groups is supposed to be potentially rele-
vant, when the confidence interval bars lie outside the ±1.0 SD limits 
(case c). Case b indicates statistical significance, but no clear biologi-
cal relevance. Case d indicates no statistical significance, but no clear 
negation of biological relevance. This figure is Fig. 1 of the study by 
Zeljenková et al. (2014)
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results of the analysis of the 1st batch are listed in Table 3 
of the Electronic Supplementary Material and the results of 
the analysis of the 2nd batch in Table 4 of the Electronic 
Supplementary Material. 
Feed composition analysis of the 1st batch of the four 
diets
The 1st batch of all four diets showed similar levels of 
most of the analysed proximates (ash, total carbohydrates, 
fat, protein), starch, fibres, amino acids, fatty acids, min-
erals, vitamins, sugars, anti-nutrients and secondary 
metabolites. In the case of folic acid, the conventional 
2 and 11 % GMO diets contained somewhat lower lev-
els and the 33 % GMO diet a somewhat higher level if 
compared to the control diet. The lead level was some-
what higher in the 11 % GMO diet and somewhat lower 
in the 33 % GMO diet when compared to the control diet. 
The β-, γ- and δ-tocopherol levels were similar in the con-
trol and 11 % GMO diets, while they were lower in the 
conventional 2 and 33 % GMO diets. The glucose level 
was somewhat lower in the 11 % GMO and 33 % GMO 
diets, the maltose level lower in the conventional 2 and 
11 % GMO diets, the raffinose as well as the sucrose 
levels lower in the conventional 2 and 11 % GMO diets 
and higher in the 33 % GMO diet and the stachyose level 
somewhat lower in the conventional 2 diet and somewhat 
higher in the 33 % GMO diet if compared to the control 
diet. The phytic acid level was similar in the control, 11 % 
GMO and 33 % GMO diets and higher in the conven-
tional 2 diet. The trypsin inhibitor level was higher in the 
33 % GMO diet than in the control diet. The levels of the 
soy isoflavones daidzin, genistin and glycitin were higher 
in the 33 % GMO diet, while those of genistein and gly-
citein were lower in the 33 % GMO diet when compared 
to those of the control diet. Very low amounts of atropine 
were detected in all four diets. None of the measured con-
centrations/detected differences were considered to affect 
the health of the rats in any way.
Low and similar amounts of polychlorinated dibenzo-
p-dioxins and dibenzofurans, polychlorinated biphenyls, 
polycyclic aromatic hydrocarbons, most mycotoxins and 
nitrosamines were detected in the 1st batch of all four diets 
(Table 3, Electronic Supplementary Material). Among the 
mycotoxins analysed, fumonisins B1, B2 and B3 were pre-
sent at clearly higher levels in the control diet than in the 
other three diets. Beauvericin was present in the control 
and 11 % GMO diets at levels slightly above the limit of 
quantitation, whereas deoxynivalenol was present in the 
control and conventional 2 diets slightly above the limit 
of quantitation. Residues of the pesticides deltamethrin, 
ethoxyquin, piperonyl butoxide and pirimiphos-methyl 
were detected in all diets, chlorpyrifos in the control diet 
and N-desethyl-pyrimiphos-methyl in the 33 % GMO diet, 
but at levels that were considered not to affect the health 
of the rats in any way (Table 3, Electronic Supplementary 
Material).
As expected, the MON810 event was detected in the 1st 
batch of diets containing 11 and 33 % of the GM MON810 
maize at the DNA and the protein level (Table 2). More-
over, the 1st batch of the control and the conventional 2 
diets contained non-quantifiable traces of the MON810 
event (Table 2). The ratios for the MON810 event level 
and the Cry1Ab protein content between the diet contain-
ing 11 % GMO and the one containing 33 % GMO were 
3 and 2.1, respectively (Table 2). It should be noted that 
the detection of the cry1Ab gene in the diet sample of the 
33 % GM maize failed for an unknown reason, while the 
MON810 event was quantified and the protein itself was 
detected as expected. While it can only be speculated as to 
why the cry1ab-gene-specific PCR amplicon (described by 
Scholtens et al. 2013) could not be detected, hypothetical 
yet unverified contributing factors may include design (e.g. 
impaired binding of selected primer to primer target site) 
and suboptimal reaction conditions (temperature, master 
mix).
Following irradiation, microorganisms such as coliforms, 
Enterobacteriaceae, yeast and moulds were not detected in 
the diets (Table 3, Electronic Supplementary Material).
Feed composition analysis of the 2nd batch of the four 
diets
The 2nd batch of the four diets showed similar levels of most 
of the analysed proximates (ash, total carbohydrates, fat, 
protein), starch, fibres, amino acids, fatty acids, minerals, 
vitamins, sugars, anti-nutrients and secondary metabolites. 
The 33 % GMO diet contained a higher level of folic acid if 
compared to the control diet. The arsenic and selenium lev-
els were higher in the conventional 2, 11 % GMO and 33 % 
GMO diets when compared to the control diet, while the cad-
mium level was higher in the control diet than in the other 
three diets. The β-, γ- and δ-tocopherol levels were similar in 
the control and 11 % GMO diets, while they were lower in the 
conventional 2 and 33 % GMO diets. The δ-tocopherol level 
was higher in the control diet than in the other three diets. The 
maltose, raffinose, stachyose and sucrose levels were higher 
in the conventional 2, 11 % GMO and 33 % GMO diets when 
compared to the control diet. Trypsin inhibitor activity was 
measured in the conventional 2 and 11 % GMO diets. The 
levels of the soy isoflavones daidzein, daidzin, genistein and 
genistin were higher in the control diet than in the other three 
2538 Arch Toxicol (2016) 90:2531–2562
1 3
diets, while those of glycitin were similar in the conventional 
2 and 11 % GMO diets and higher than in the control and 
33 % GMO diets. Very low levels of atropine and ergot alka-
loid concentrations slightly above the limit of quantification 
were detected in the control diet. None of the measured con-
centrations/detected differences were considered to affect the 
health of the rats in any way.
Low and similar amounts of polychlorinated dibenzo-
p-dioxins and dibenzofurans, polychlorinated biphenyls, 
polycyclic aromatic hydrocarbons, most mycotoxins 
and nitrosamines were detected in the 2nd batch of all 
four diets (Table 4, Electronic Supplementary Material). 
Among the mycotoxins analysed, fumonisins B1, B2 and 
B3 were present at higher levels in the control diet than 
in the other three diets. Furthermore, beauvericin was 
present in the control and 11 % GMO diets, whereas 
deoxynivalenol was present in the four diets at levels 
slightly above the limit of quantitation. Residues of the 
pesticides deltamethrin, ethoxyquin, piperonyl butoxide 
and pirimiphos-methyl were detected in all diets, hexy-
thiazox and N-desethyl-pirimiphos-methyl in the 33 % 
GMO diet and chlorpyrifos-methyl in the control diet, 
but at levels that were considered not to affect the health 
of the rats in any way (Table 4, Electronic Supplemen-
tary Material).
The MON810 event was detected in the 2nd batch 
of diets containing 11 and 33 % of the GM MON810 
maize at the DNA and the protein level, while the MON 
810 event was not detected in the 2nd batch of control 
and conventional 2 diets (Table 2). The ratios for the 
MON810 event level and the Cry1Ab protein content 
between the diet containing 11 % GMO and the one 
containing 33 % GMO were 3.1 and 2.6, respectively 
(Table 2). It should be noted that the detection of the 
cry1Ab gene in the diet sample of the 11 % GM maize 
failed for any unknown reason, while the MON810 event 
was quantified and the protein itself was detected as 
expected.
Following irradiation, microorganisms such as coli-
forms, Enterobacteriaceae, yeast and moulds were not 
detected in the diets (Table 4, Electronic Supplementary 
Material).
Body weight and feed consumption2
The body weight of the male rats in all four groups 
increased with time (Fig. 2a; Table 5, Electronic Sup-
plementary Material). At the end of the study, the male 
rats fed the control, conventional 2 and 11 % GMO diet 
reached a mean body weight of 594, 598 and 592 g, respec-
tively, while those fed the 33 % GMO diet weighed 550 g 
(Table 5, Electronic Supplementary Material), whereby the 
difference in the least square means of the body weight 
between the 33 % GMO diet-fed rats and the control group 
was not statistically significant. The body weight of the 
female rats in the four experimental groups also increased 
time dependently (Fig. 2b; Table 5, Electronic Supple-
mentary Material). At the end of the study, the female 
rats fed the control, conventional 2, 11 % GMO and 33 % 
GMO diet reached a mean body weight of 367, 358, 339 
and 344 g, respectively (Table 5, Electronic Supplemen-
tary Material), whereby the differences of the least square 
means between the control and the 11 % GMO as well as 
the 33 % GMO group were not statistically significant.
Feed consumption in male rats increased in the first 
5 weeks, remained relatively constant until week 31 and 
slightly increased until week 49 (Fig. 3a; Table 6, Elec-
tronic Supplementary Material). Males being fed the con-
ventional 2, 11 % GMO or 33 % GMO diet consumed less 
feed (in the order 33 % GMO <11 % GMO <conventional 
2) than the males in the control group (Table 6, Electronic 
Supplementary Material). Feed consumption in female 
rats increased in the first 4 weeks, remained relatively con-
stant until week 35 and then slightly increased until week 
39 (Fig. 3b; Table 6, Electronic Supplementary Material). 
Feed consumption was similar in rats fed the control, the 
conventional 2 or the 11 % GMO diet, while it was slightly 
lower in female rats fed the 33 % GMO diet (Table 6, Elec-
tronic Supplementary Material). The differences of the least 
square means in feed consumption between the control and 
2 The body weight and feed consumption data were analysed by 
applying mixed models. In this context, a statistically significant dif-
ference means that the mixed model analysis identified a group effect.
Table 2  Cry1Ab levels the different diets used in the 1-year feeding trial
Control Conventional 2 11 % GMO 33 % GMO
First batch of diets
 MON810 maize event–genetically modified DNA (%) Detected, not quantifiable Detected, not quantifiable 10.4 31.3
 Cry1Ab (ng/mg protein) Not detected Not detected 0.6 1.27
Second batch of diets
 MON810 maize event–genetically modified DNA (%) Not detected Not detected 12.8 40.2
 Cry1Ab (ng/mg protein) Not detected Not detected 0.47 1.2
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the 11 % GMO, 33 % GMO and conventional 2 groups in 
male and female rats were not statistically significant.
Feed efficiency in the case of male rats was very simi-
lar in all four experimental groups (Fig. 4a; Table 7, Elec-
tronic Supplementary Material), and the same holds true 
for female rats (Fig. 4b; Table 7, Electronic Supplementary 
Material). No statistically significant differences between 
the least square means were observed among the different 
experimental groups in male as well as in female rats.
Clinical and ophthalmological observations
The following three rats had to be killed before the end of 
the feeding trial: (1) rat No. 15: a male rat fed the 33 % 
GMO diet was killed on day 227 due to a paraplegia of 
the hind limbs that led to strong loss of weight; (2) rat No. 
131: a female rat fed the 11 % GMO diet was killed on day 
244 due to the development of a yolk sac carcinoma local-
ized in the right ovary that led to multiple metastases in the 
abdominal cavity; and (3) rat No. 159: a female rat fed the 
control diet was killed day 327 due to the development of a 
mammary gland comedocarcinoma. A very limited number 
of clinical signs were observed in the rest of the animals 
(Table 3). The ophthalmological analyses revealed no alter-
ations in all four experimental groups immediately before 
starting the feeding trial as well as at the end of the study.
Haematology, clinical biochemistry and urine 
analyses3
The haematology parameters measured in the blood sam-
ples of male and female rats at 3, 6 and 12 months are 
shown in Table 4 and the corresponding SES graphs with 
the data at t = 12 months in Figs. 5a–c and 6a–c.
After 3 months, no statistically significant differences 
were observed when the haematology parameters WBC, 
RBC, HGB, HCT, MCV, MCH, MCHC, PLT and LYM of 
the control, conventional 2, 11 % GMO and 33 % GMO 
groups were compared, this being the case of male as well 
as female rats (Table 4). The differential leucocyte count 
showed that the percentage of eosinophils was significantly 
higher in female rats fed the 33 % GMO diet than in the 
animals fed the control diet (Table 4).
3 For all the haematology and clinical biochemistry endpoints as well 
as for the relative organ weights, SES was calculated. In this context, 
a statistically significant difference means that the confidence inter-
val of the SES to the control does not include the zero value, while 
a difference, which is not statistically significant, means that the 
confidence interval of the SES to the control includes the zero value 
(Fig. 1).
After 6 months, no statistically significant differences 
were observed when the haematology parameters and the 
differential leucocyte count of male and female rats fed the 
control, conventional 2, 11 % GMO and 33 % GMO diets 
were compared, except for the percentage of white blood 
cells, which was significantly higher in male rats fed the 
11 % GMO and the 33 % GMO diets, and the percentage 
of eosinophils, which was significantly lower in female rats 
fed the 33 % GMO diet when compared to the correspond-
ing animals fed the control diet (Table 4).
After 12 months, no statistically significant differences 
were observed when the haematology parameters and the 
differential leucocyte count of male and female rats fed 
the control, conventional 2, 11 % GMO and 33 % GMO 
diets were compared, except for the percentage of eosin-
ophils, which was increased in male as well as in female 
rats fed the conventional 2 and the 11 % GMO diets when 
compared to the corresponding animals fed the control diet 
(Table 4; Figs. 5a, b, 6a, b).
With the classical statistical methods, an increase in the 
number of WBC after 6 months was additionally observed 
in female rats of the conventional 2 group if compared to 
the control group (Table 4).
The clinical biochemistry parameters measured in serum 
of male and female rats are shown in Table 5 and the cor-
responding SES graphs with the data at t = 12 months in 
Figs. 5a–c and 6a–c. After 3 months, no statistically sig-
nificant differences were observed when all biochemical 
parameters of male and female rats fed the control, con-
ventional 2, 11 % GMO and 33 % GMO diets were com-
pared, except for the AST activity in male rats fed the con-
ventional 2 diet and the Cl levels in male rats fed the 33 % 
GMO diet, which were significantly decreased when com-
pared to male rats fed the control diet (Table 5).
After 6 months, the AST activity was significantly 
increased in male rats fed the 11 % GMO diet, the P level 
was significantly increased in male rats fed the 33 % 
GMO diet, and the Cl and Na levels were significantly 
decreased in male rats fed the conventional 2 diet if com-
pared to the male rats fed the control diet (Table 5). No 
statistically significant differences were observed when 
all measured biochemical parameters of female rats in all 
four experimental groups were compared, except for the 
GLU level, which was significantly lower in female ani-
mals fed the 33 % GMO diet than in those fed the control 
diet (Table 5).
After 12 months, the GLU level was significantly 
reduced and the P level significantly increased in male 
rats fed the 11 % GMO diet if compared to those fed the 
control diet (Table 5; Fig. 5b). No statistically significant 
differences were observed when all measured biochemical 
parameters of female rats in all four experimental groups 
were compared, except for the CREA level, which was 
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significantly higher in animals fed the 11 % GMO diet, and 
the K level, which was significantly lower in animals fed 
the conventional 2 diet than in those fed the control diet 
(Table 5; Fig. 6a, b).
With the classical statistical methods, an increase in the 
AST activity was additionally observed in female rats fed 
the 33 % GMO diet for 12 months when compared to the 
corresponding control group (Table 5).
Fig. 2  Male and female rat body weights in the 1-year feeding trial. Line plots (with confidence intervals) of mean male (a) and female (b) body 
weights (g) per cage
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Urinalysis data of male rats fed the control, conven-
tional 2, 11 % GMO or 33 % GMO diet for 3, 6 and 
12 months are shown in Table 6, while the urinalysis data 
of female rats fed the control, conventional 2, 11 % GMO 
or 33 % GMO diet for 3, 6 and 12 months are shown in 
Table 7. In male rats, the semi-quantitative evaluation of 
protein, ketones, nitrate, leucocytes and erythrocytes did 
not reveal major differences between the four experimen-
tal groups, while a tendency to a higher pH was observed 
in urine samples from rats fed the 11 % GMO and 33 % 
GMO diets if compared to those of animals fed the con-














































0 3 6 9 12 15 18 21 24 27 30 33 36 39 42 45 48 51 54
0 3 6 9 12 15 18 21 24 27 30 33 36 39 42 45 48 51 54
group control 11% GMO 33% GMO conventional 2
A
week
group control 11% GMO 33% GMO conventional 2
B
Fig. 3  Male and female rat feed consumption in the 1-year feeding trial. Line plots of mean feed consumption per cage (g) and per week (weeks 
1–13) or per 2 weeks (weeks 15–53) in the case of male (a) and female rats (b)
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osmolality increased with age and to a similar extent in 
all four experimental groups. In female rats, the semi-
quantitative evaluation of protein, ketones, nitrate, leuco-
cytes and erythrocytes as well as the pH determination 
did not reveal major differences between the four experi-
mental groups, whereas osmolality increased with age 
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Fig. 4  Male and female rat feed efficiency in the 1-year feeding trial. Line plots of mean feed efficiency per cage (g) and per week (weeks 1–13) 
or per 2 weeks (weeks 15–53) in the case of male (a) and female rats (b)
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Relative organ weights, gross necropsy 
and histopathology2,4
No statistically significant differences were observed when 
the relative weight of all organs in male rats fed the con-
trol, conventional 2, 11 % GMO and 33 % GMO diets was 
compared (Table 8). In female rats fed the conventional 
2 diet, the relative weight of the right ovary was signifi-
cantly lower than in control female rats, whereas no sta-
tistically significant differences were observed when the 
relative weight of all other organs in the female animals of 
all four experimental groups was compared (Table 8). The 
weight of the pair organs (i.e. the kidneys, adrenal glands, 
testes and epididymides in male rats, the kidneys, adrenal 
glands and ovaries in the female rats) was also analysed as 
a grouped value, as recommended by Sellers et al. (2007), 
and no statistically significant differences between the 
groups were observed (data not shown).
With the classical statistical methods, the relative left 
kidney weight of female rats fed the 33 % GMO diet was 
additionally increased when compared to the corresponding 
control group value (Table 8).
4 Slides of all tissues analysed may be looked at on request at the 
Laboratory of Toxicology of the Slovak Medical University (Brati-
slava, Slovakia).
The gross necropsy observations and histopathologi-
cal findings in all male rats having been fed the control and 
the 33 % GMO diets are shown in Table 9, while those of 
all female animals having been fed the control and the 33 % 
GMO diets are shown in Table 10. Five out of 20 male rats 
fed the control diet and 1 out of 20 male rats fed the 33 % 
GMO diet showed macroscopic alterations, which were not 
accompanied by corresponding histopathological alterations 
when analysed under the light microscope (Table 9). Eleven 
out of 20 female rats fed the control diet showed macroscopic 
alterations: in 1 out of the 11 animals showing macroscopic 
alterations, no histopathological alterations were detected 
(Table 10). Sixteen out of 20 female rats fed the 33 % GMO 
diet showed macroscopic alterations: in 5 out of the 16 ani-
mals showing macroscopic alterations, no histopathological 
alterations were observed (Table 10). Moreover, as stated 
in the OECD Test Guideline 452 (OECD 2009), all tissues 
showing macroscopic abnormalities in the other experimen-
tal groups should also be analysed histopathologically. These 
data are shown for the animals having been fed the con-
ventional 2 diet in Table 8 of the Electronic Supplementary 
Material and for those having been fed the 11 % GMO diet in 
Table 9 of the Electronic Supplementary Material. 
The incidence of the different non-cancerous lesions 
in the male rats fed the control and the 33 % GMO diets 
was similar and very low (i.e. in most cases, findings in 
1–2 animals per group, if at all, were observed) (Table 11). 
Table 3  Clinical observations in male and female Wistar Han RCC rats during the 1-year feeding trial
a Rats 15, 131 and 159 were killed on days 227, 244 and 327, respectively
Group Animal no. Week no. Clinical observations
Male rats
 33 % GMO 2 10 Diarrhoea
7 25 Bite wounds on the left scapula and left ventral side
15a 31 Paraplegia of the hind limbs
 Control 50 6 Diarrhoea
 Conventional 2 63 9 Diffuse epistaxis, chromodacryorrhea
79 40 Exophthalmos (both eyes), diarrhea
Female rats
 33 % GMO 102 43 Chromodacryorrhea
106 25 Hair loss between the scapulae
107 23–53 Bite wound, pruritus and scabs between the scapulae
109 26 Tail wound
 11 % GMO 126 30 Bite wound between the scapulae
129 42–53 Hair loss on the left side of the face
131a 33–34 Weight loss, apathy, piloerection, hypersalivation, haematemesis,  
chromodacryorrhea, enlarged abdominal cavity, abdominalgia, dyspnoea
135 26 Tail wound
 Control 144 42–53 Maxilla deformation, exophthalmos, chromodacryorrhea, dyspnoea
147 9 Bite wound on the back
159a 31–47 Mammary gland abscess
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The incidence of the different non-cancerous lesions in 
the female rats fed the control and the 33 % GMO diets 
was similar and very low (i.e. in most cases, findings in 
1–2 animals per group were detected), except for cysts in 
the ovaries, which were observed in 4 out of 19 rats fed 
the control diet and in 6 out of 20 rats fed the 33 % GMO 
diet (Table 12). The number of benign and malignant 
tumours detected in rats fed the control or 33 % GMO diet 
was extremely low (Table 13). Benign tumours were not 
observed in male rats of either group, while one out of 19 
female rats fed the control diet developed a lipoma, one out 
of 19 female rats fed the control diet a cutaneous papilloma 
and one out of 20 female rats fed the 33 % GMO diet a 
lipoma. Malignant tumours were not detected in male rats 
of either group, while one out of 20 female rats fed the con-
trol diet developed a mammary gland comedocarcinoma. 
Moreover, a pituitary haemangioma in the conventional 2 
group (Table 8, Electronic Supplementary Material) and a 
yolk sac carcinoma in the 11 % GMO group (Table 9, Elec-
tronic Supplementary Material) were observed.
Fig. 5  Standardized effect size graphs for the comparison of the 
body weight, relative organ weight, haematology, clinical biochemis-
try and differential leucocyte count data between the control and the 
conventional 2 (A), 11 % GMO (B) and 33 % GMO (C) groups in the 
case of male rats in the 1-year feeding trial
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Comparison of the SES analysis approach 
versus the classical statistical analysis approach
The significances identified by SES analysis and those 
identified by the appropriate classical statistical tests, which 
were selected according to a decision tree described by the 
OECD (2012) as well as by Schmidt et al. (2015b), were 
99 % in agreement. In the case of 609 endpoint compari-
sons, the SES approach detected 21 significant differences, 
whereby four of them were not identified by the classical 
approach. The classical decision tree-based approach found 
19 significant differences, and two of them were not identi-
fied by the SES approach.
If solely the Kruskal–Wallis test followed by the Wilcoxon 
test was applied to all 609 endpoint comparisons, 11 signifi-
cant differences were detected. If solely the ANOVA followed 
by the Dunnett test was applied to all 609 endpoint compari-
sons, 12 significant differences were observed. If solely the 
ANOVA followed by the t test was applied to all 609 end-
point comparisons, 39 significant differences were detected.
Fig. 5  continued
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Discussion
The compositional analysis of the diets
The compositional analysis of the diets showed that the 
differences between the diets containing the near-isogenic 
non-GM maize, MON810 maize or conventional 2 maize 
variety were irrelevant, except for fumonisins in the near-
isogenic non-GM maize, and not considered to impair the 
health of the experimental animals.
In order to evaluate whether the contamination of the 
control diet with fumonisins could have influenced the 
outcome of the study, the dose of the ingested fumonisins 
throughout the feeding trial was calculated by taking into 
account the feed consumption and the body weight. In the 
scientific literature, the lowest no observed adverse effect 
level (NOAEL) values reported for fumonisin B1 in rats 
were 0.2 mg/kg body weight/day (endpoint: kidney toxic-
ity) in a subchronic toxicity study (Voss et al. 1995) and 
0.25 mg/kg body weight/day (endpoint: kidney toxicity) 
Fig. 6  Standardized effect size graphs for the comparison of the 
body weight, relative organ weight, haematology, clinical biochemis-
try and differential leucocyte count data between the control and the 
conventional 2 (a), 11 % GMO (b) and 33 % GMO (c) groups in the 
case of female rats in the 1-year feeding trial
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in a chronic toxicity study (US-NTP 1999). The calculated 
fumonisin B1–3 dose in male rats in the first week of the 
feeding trial was 0.2 mg/kg body weight/day and thereafter 
continuously declined until the end of the study, while in 
female rats the fumonisin B1–3 dose was below the value of 
0.2 mg/kg body weight/day in the first week of the feeding 
trial and continued to decrease until the end of the study 
(Fig. 7 shows the calculated fumonisin B1–3 dose for male 
and female rats during the first 13 weeks of the feeding 
trial). Hence, at no time during the 1-year feeding trial did 
the fumonisin B1–3 dose in male and female rats exceed the 
NOAEL value for fumonisin B1.
High levels of fumonisins in the diet are known to 
induce nephrotoxicity and hepatotoxicity in rats (US-NTP 
1999). The functional renal and hepatic parameters meas-
ured in the blood of the rats fed the control diet for 1 year 
did not reveal any sign of nephrotoxicity and hepatotox-
icity. Males and females of the control group showed no 
relevant differences in the incidence of histopathological 
alterations in the kidney if compared to those of the 33 % 
GMO group, which in both cases was very low, and no pre-
neoplastic and/or neoplastic lesions were identified. No his-
topathological alterations in the liver of male and female 
Wistar Han RCC rats fed the control diet for 1 year were 
Fig. 6  continued
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Table 5  Mean values ± standard deviations (SD) of clinical biochemistry parameters in the serum of male and female Wistar Han RCC rats at 
3, 6 and 12 months
Parameter Males Females
Control1 Conventional 22 11 % GMO3 33 % GMO4 Control5 Conventional 26 11 % GMO7 33 % GMO8
At 3 months
 ALP (µkat/l) 1.18 ± 0.12 1.09 ± 0.20 1.10 ± 0.22 1.13 ± 0.19 0.62 ± 0.07 0.61 ± 0.12 0.69 ± 0.06 0.58 ± 0.20
 ALT (µkat/l) 0.47 ± 0.08 0.42 ± 0.07 0.46 ± 0.03 0.52 ± 0.09 0.49 ± 0.37 0.34 ± 0.11 0.52 ± 0.22 0.51 ± 0.14
 AST (µkat/l) 2.07 ± 0.19 1.67 ± 0.16b,c 2.27 ± 0.64 2.50 ± 0.33 2.68 ± 1.02 1.78 ± 0.61 3.06 ± 1.24 3.44 ± 0.75
 ALB (g/l) 38.44 ± 2.08 37.91 ± 1.17 39.34 ± 2.61 39.16 ± 2.74 46.64 ± 3.29 45.18 ± 3.53 45.73 ± 0.78 48.47 ± 2.39
 TP (g/l) 63.53 ± 1.83 62.80 ± 0.46 64.95 ± 3.45 64.25 ± 2.89 70.07 ± 2.80 67.46 ± 3.69 68.78 ± 1.44 71.76 ± 2.81
 GLU 
(mmol/l)
6.46 ± 0.57 6.54 ± 0.83 6.26 ± 0.87 6.06 ± 0.68 6.62 ± 0.50 6.78 ± 1.40 7.29 ± 0.59 6.10 ± 0.78
 CREA 
(µmol/l)
48.21 ± 6.06 50.29 ± 6.44 48.10 ± 2.56 46.99 ± 4.65 50.72 ± 6.91 54.41 ± 8.42 49.39 ± 3.22 52.28 ± 7.31
 U (mmol/l) 6.21 ± 0.59 6.73 ± 0.67 5.88 ± 0.58 5.97 ± 0.48 6.18 ± 0.41 6.31 ± 0.80 6.61 ± 0.42 6.57 ± 0.64
 CHOL 
(mmol/l)
2.03 ± 0.18 2.10 ± 0.13 1.93 ± 0.08 1.99 ± 0.12 1.88 ± 0.33 1.71 ± 0.15 2.13 ± 0.26 1.87 ± 0.14
 TRG 
(mmol/l)
0.80 ± 0.12 1.05 ± 0.22 0.88 ± 0.20 0.80 ± 0.15 0.71 ± 0.16 0.61 ± 0.09 0.57 ± 0.07 0.67 ± 0.14
 Ca (mmol/l) 2.50 ± 0.04 2.48 ± 0.04 2.45 ± 0.07 2.44 ± 0.03 2.57 ± 0.06 2.58 ± 0.06 2.56 ± 0.02 2.56 ± 0.02
 Cl (mmol/l) 104.80 ± 1.04 104.60 ± 0.96 103.20 ± 0.97 102.60 ± 1.39a,c 101.70 ± 2.71 103.10 ± 1.64 100.20 ± 3.58 100.00 ± 1.32
 K (mmol/l) 4.80 ± 0.18 4.78 ± 0.19 5.37 ± 1.14 5.50 ± 1.27 5.13 ± 0.86 4.66 ± 0.32 5.02 ± 0.62 5.48 ± 0.84
 Na (mmol/l) 144.50 ± 1.46 143.50 ± 0.50 144.10 ± 1.67 144.20 ± 1.92 141.90 ± 3.13 143.40 ± 1.95 141.60 ± 2.22 141.30 ± 1.15
 P (mmol/l) 2.08 ± 0.16 2.08 ± 0.20 2.36 ± 0.39 2.43 ± 0.35 2.02 ± 0.41 2.00 ± 0.29 1.91 ± 0.13 1.99 ± 0.27
At 6 months
 ALP (µkat/l) 1.26 ± 0.13 1.42 ± 0.12 1.31 ± 0.23 1.17 ± 0.21 0.63 ± 0.15 0.60 ± 0.16 0.59 ± 0.21 0.53 ± 0.08
 ALT (µkat/l) 0.39 ± 0.05 0.43 ± 0.11 0.40 ± 0.03 0.45 ± 0.21 0.59 ± 0.37 0.61 ± 0.26 0.48 ± 0.30 0.58 ± 0.37
 AST (µkat/l) 2.42 ± 0.19 3.26 ± 1.21 2.54 ± 0.48c 3.38 ± 0.81c 3.15 ± 1.60 3.42 ± 1.24 3.13 ± 1.08 3.87 ± 1.45
 ALB (g/l) 38.17 ± 2.54 36.83 ± 1.53 38.60 ± 0.64 39.20 ± 1.04 45.18 ± 3.26 46.91 ± 2.83 45.68 ± 1.97 47.17 ± 4.00
 TP (g/l) 68.31 ± 3.76 66.91 ± 2.78 68.53 ± 1.40 69.17 ± 1.42 72.59 ± 3.15 75.29 ± 3.15 75.00 ± 2.54 75.53 ± 3.55
 GLU 
(mmol/l)
7.05 ± 1.09 7.89 ± 0.98 6.15 ± 0.40 6.07 ± 1.00 7.85 ± 0.44 7.56 ± 0.64 7.00 ± 0.63 6.07 ± 1.46a,c
 CREA 
(µmol/l)
44.38 ± 6.29 42.74 ± 4.79 42.45 ± 3.78 44.72 ± 3.72 41.60 ± 2.55 42.31 ± 2.61 44.29 ± 1.43 48.92 ± 8.42
 U (mmol/l) 5.54 ± 0.91 5.84 ± 0.61 5.27 ± 0.12 5.29 ± 0.20 6.39 ± 0.56 5.81 ± 0.51 6.23 ± 0.31 6.11 ± 0.49
 CHOL 
(mmol/l)
2.26 ± 0.19 2.41 ± 0.22 2.21 ± 0.14 2.37 ± 0.19 2.08 ± 0.32 2.11 ± 0.30 2.47 ± 0.21 2.20 ± 0.25
 TRG 
(mmol/l)
1.17 ± 0.36 1.10 ± 0.07 1.12 ± 0.18 1.08 ± 0.21 0.71 ± 0.17 0.72 ± 0.06 0.58 ± 0.15 0.58 ± 0.23
 Ca (mmol/l) 2.63 ± 0.07 2.61 ± 0.11 2.62 ± 0.04 2.62 ± 0.09 2.57 ± 0.07 2.59 ± 0.05 2.59 ± 0.04 2.54 ± 0.05
 Cl (mmol/l) 103.90 ± 1.39 101.40 ± 1.29a,c 102.80 ± 0.76 103.10 ± 1.75 100.90 ± 1.39 99.70 ± 2.36 100.50 ± 2.06 100.30 ± 2.56
 K (mmol/l) 4.97 ± 0.44 5.16 ± 0.18 5.24 ± 0.25 5.63 ± 0.64 4.90 ± 0.48 4.94 ± 0.22 5.15 ± 0.70 5.36 ± 0.98
 Na (mmol/l) 146.30 ± 1.30 144.20 ± 1.04a,c 146.80 ± 0.57 146.50 ± 0.79 143.70 ± 1.79 144.40 ± 1.98 143.30 ± 2.51 144.80 ± 2.31
 P (mmol/l) 1.65 ± 0.20 1.51 ± 0.27 2.05 ± 0.28a,c 2.01 ± 0.23c 1.36 ± 0.19 1.37 ± 0.07 1.64 ± 0.22 1.87 ± 0.47
At 12 months
 ALP (µkat/l) 1.31 ± 0.24 1.23 ± 0.20 1.42 ± 0.23 1.17 ± 0.23 0.59 ± 0.25 0.51 ± 0.07 0.56 ± 0.13 0.53 ± 0.14
 ALT (µkat/l) 0.80 ± 0.34 0.75 ± 0.34 0.71 ± 0.11 0.70 ± 0.21 0.68 ± 0.17 0.79 ± 0.33 0.61 ± 0.16 0.86 ± 0.34
 AST (µkat/l) 2.58 ± 0.79 2.48 ± 0.63 2.50 ± 0.49 2.76 ± 0.62 2.46 ± 0.79 2.69 ± 0.71 2.39 ± 0.57 3.36 ± 1.06a
 ALB (g/l) 40.04 ± 1.94 39.46 ± 1.65 40.52 ± 1.47 39.76 ± 1.94 42.62 ± 2.07 42.85 ± 3.01 43.62 ± 3.40 42.77 ± 2.48
 TP (g/l) 69.39 ± 1.93 68.64 ± 2.45 69.75 ± 1.57 68.06 ± 2.50 71.69 ± 2.70 71.92 ± 2.70 72.70 ± 3.90 70.14 ± 2.92
 GLU 
(mmol/l)
6.28 ± 1.13 6.17 ± 0.75 5.32 ± 0.49c 5.65 ± 1.08 5.47 ± 0.51 5.77 ± 0.80 5.51 ± 0.95 4.91 ± 0.65
 CREA 
(µmol/l)
42.53 ± 4.38 40.31 ± 3.53 42.03 ± 3.24 39.40 ± 4.37 41.50 ± 2.96 42.07 ± 4.30 44.91 ± 2.66b,c 42.85 ± 4.61
 U (mmol/l) 5.24 ± 0.71 5.52 ± 0.51 5.20 ± 0.69 5.12 ± 0.69 5.31 ± 0.67 4.81 ± 0.32 5.58 ± 0.66 5.34 ± 0.38
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observed. Taken together, based on the above-mentioned 
calculations and determined parameters, it is concluded 
that the fumonisin contamination of the control diet did not 
influence the outcome of the study.
MON810 was present in the control and conventional 
maize varieties at the limit of quantitation (approximately 
0.1 %), while in the corresponding diets it was non-detect-
able in some diet samples and non-quantifiable (i.e. below 
the limit of quantification) in others. This indicates that 
MON810 occurred at trace levels at best, various orders of 
magnitude below that in the maize and diet materials des-
ignated as MON810. The source of the admixture was not 
identified. Given that ≥99.9 % of maize used in the diets 
fed to the non-GM groups is not MON810, these traces 
of admixture were not considered to impact on the valid-
ity of the comparison of animal groups fed the non-GM 
diets with those fed MON810 for possible effects linked to 
MON810 consumption.
Differences in the mean body weight between control 
and GMO‑fed rats
Although not statistically significant, the male rats fed the 
33 % GMO diets had a lower mean body weight than the 
male animals fed the control diet throughout the study, 
while there were no differences in the body weight between 
male rats fed the 11 % GMO diet and those fed the con-
trol diet. The mean body weight of female rats fed the 11 % 
GMO and 33 % GMO diets was lower than that of the 
animals fed the control diet throughout the study, but the 
differences were not statistically significant, and the mean 
body weight of the rats fed the 11 % GMO and 33 % GMO 
diets was similar. The lower mean body weight of the 
GMO-fed animals correlated with a lower feed consump-
tion. It was hypothesized that the lower feed intake could 
be due to an altered hardness and/or particle size distribu-
tion of the pellets containing the GM maize. However, an 
Table 5  continued
Parameter Males Females
Control1 Conventional 22 11 % GMO3 33 % GMO4 Control5 Conventional 26 11 % GMO7 33 % GMO8
 CHOL 
(mmol/l)
2.76 ± 0.34 2.69 ± 0.37 2.55 ± 0.29 2.73 ± 0.49 2.20 ± 0.39 2.46 ± 0.52 2.55 ± 0.42 2.24 ± 0.29
 TRG 
(mmol/l)
1.44 ± 0.43 1.57 ± 0.64 1.41 ± 0.54 1.45 ± 0.46 1.05 ± 0.29 1.01 ± 0.30 0.98 ± 0.28 0.90 ± 0.23
 Ca (mmol/l) 2.66 ± 0.07 2.66 ± 0.10 2.64 ± 0.06 2.61 ± 0.05 2.60 ± 0.03 2.61 ± 0.04 2.62 ± 0.07 2.59 ± 0.04
 Cl (mmol/l) 105.70 ± 2.50 105.30 ± 2.12 104.45 ± 1.54 103.70 ± 2.24 101.90 ± 1.91 101.40 ± 1.91 102.55 ± 1.50 102.95 ± 1.54
 K (mmol/l) 5.41 ± 0.27 5.53 ± 0.49 5.76 ± 0.51 5.54 ± 0.31 4.71 ± 0.23 4.41 ± 0.20b,c 4.67 ± 0.50 4.88 ± 0.64
 Na (mmol/l) 145.50 ± 2.17 145.15 ± 1.49 145.80 ± 1.23 143.65 ± 1.72 141.80 ± 1.09 142.45 ± 1.54 142.35 ± 1.08 142.70 ± 1.55
 P (mmol/l) 1.89 ± 0.19 1.98 ± 0.26 2.12 ± 0.15b,c 1.95 ± 0.21 1.52 ± 0.25 1.46 ± 0.31 1.57 ± 0.27 1.63 ± 0.32
ALP alkaline phosphatase, ALT alanine aminotransferase, AST aspartate aminotransferase, ALB albumin, TP total protein, GLU glucose, CREA 
creatinine, U urea, CHOL cholesterol, TRG triglycerides, Ca calcium, Cl chloride, K potassium, Na sodium, P phosphorus
1 10, 10 and 20 male rats fed the diet containing 33 % near-isogenic non-GM maize for 3, 6 or 12 months, respectively, were analysed
2 10, 10 and 20 male rats fed the diet containing 33 % conventional 2 maize for 3, 6 or 12 months, respectively, were analysed
3 10 (9 in the case of ALT), 10 and 20 (18 in the case of Alb, TP and K) male rats fed the diet containing 11 % GMO maize for 3, 6 or 
12 months, respectively, were analysed
4 9 (8 in the case of ALT), 10 (9 in the case of ALT) and 19 (17 in the case of ALB, TP and K) male rats fed the diet containing 33 % GMO 
maize for 3, 6 or 12 months, respectively, were analysed
5 10, 10 and 19 female rats fed the diet containing 33 % near-isogenic non-GM maize for 3, 6 or 12 months, respectively, were analysed
6 10 (9 in the case of CHOL), 10 and 20 female rats fed the diet containing 33 % conventional 2 maize for 3, 6 or 12 months, respectively, were 
analysed
7 10 (9 in the case of ALT), 10 and 19 (17 in the case of ALP) female rats fed the diet containing 11 % GMO maize for 3, 6 or 12 months, 
respectively, were analysed
7 10 (9 in the case of ALP), 10 (9 in the case of ALP) and 20 (19 in the case of AST, TP, CHOL, TRG, Ca, K and P, 18 in the case of ALP, ALT 
and ALB) female rats fed the diet containing 33 % GMO maize for 3, 6 or 12 months, respectively, were analysed
a Statistically significant difference to the control value based on one-way ANOVA and post hoc t test (p ≤ 0.05) as well as with the Dunnett test 
(p ≤ 0.05)
(a) Statistically significant difference to the control value (p < 0.05) based on one-way ANOVA and post hoc t test, post hoc Dunnett test not sig-
nificant
b Statistically significant difference to the control value (p < 0.05) based on the Wilcoxon test
c Statistically significant difference to the control value based on the 95 % confidence interval of the SES
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analysis of the physical properties of the different pellets 
by the Research Institute of Feed Technology (Braunsch-
weig, Germany) revealed no differences regarding their 
hardness and particle size distribution (data not shown). 
In the absence of any significant differences in the blood 
parameters, any significant differences in the relative organ 
weights and any histopathological alterations that could 
explain the body weight differences between the groups, it 
is concluded that the statistically not significant differences 
in body weight between the experimental groups are of no 
toxicological concern and are not event-related.
In this context, it is important to point out that in one 
of the 90-day feeding trials with the GM maize MON810, 
the so-called study A (Zeljenková et al. 2014) performed 
in the frame of the GRACE project, a similar body weight 
decrease was observed in male and female rats fed the con-
ventional variety SY-NEPAL (conventional 2), which was 
also tested in the present study. As shown in Table 14, the 
Table 6  Urinalysis data of male rats fed the control, conventional 2, 11 % GMO or 33 % GMO diet for 3, 6 and 12 months
Glucose, bilirubin and urobilinogen were negative in all analysed urine samples










0 0.25 0.75 1.5 0 0.5 1.5 5 0 11 0 25 100 500 0 10 25 50 250
Control
 3 10 10 0 0 0 1 0 7 2 10 0 10 0 0 0 7 2 1 0 0
 6 10 10 0 0 0 4 0 5 1 10 0 1 7 2 0 9 0 1 0 0
 12 10 8 1 0 1 1 2 6 1 10 0 4 5 0 1 9 0 0 0 1
Conv. 2
 3 10 9 1 0 0 0 3 6 1 10 0 8 2 0 0 10 0 0 0 0
 6 10 9 1 0 0 3 3 4 0 10 0 0 5 4 1 10 0 0 0 0
 12 10 8 1 0 1 1 4 5 0 10 0 5 3 1 1 8 1 0 0 1
11 % GMO
 3 10 10 0 0 0 0 0 10 0 10 0 10 0 0 0 8 1 1 0 0
 6 10 8 2 0 0 0 5 4 1 10 0 0 7 3 0 10 0 0 0 0
 12 10 6 2 1 1 0 1 9 0 10 0 2 5 1 2 10 0 0 0 0
33 % GMO
 3 10 10 0 0 0 2 3 5 0 9 1 8 2 0 0 8 2 0 0 0
 6 10 10 0 0 0 5 2 3 0 10 0 1 7 1 1 9 1 0 0 0
 12 10 7 2 0 1 0 3 7 0 10 0 3 4 1 2 8 1 0 1 0
Point in time (months) Number of animals pH Osmolality 
(mOsm/kg H2O)5 6 6.5 7 8
Control
 3 10 1 2 6 1 0 357.1 ± 122.7
 6 10 2 2 5 1 0 398.6 ± 109.7
 12 10 1 2 5 2 0 564.1 ± 191.5
Conv. 2
 3 10 0 1 7 2 0 441.7 ± 219.6
 6 10 5 1 3 1 0 518.5 ± 152.6
 12 10 1 4 5 0 0 501.2 ± 88.7
11 % GMO
 3 10 0 0 4 6 0 407.4 ± 134.2
 6 10 0 5 2 3 0 463.2 ± 137.7
 12 10 2 6 1 1 0 604.3 ± 211.8
33 % GMO
 3 10 0 0 2 7 1 488.4 ± 274.8
 6 10 0 3 2 4 1 540.0 ± 269.8
 12 10 1 2 2 5 0 589.9 ± 213.9
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mean body weights of male and female rats fed the conven-
tional 2 diet for 90 days in the study A were about 4–4.5 % 
lower than those of the corresponding control diet-fed rats. 
Since study A was finalized after 90 days, a further com-
parison at later points in time is not possible. Thus, mean 
body weight variations such as those reported in the pre-
sent study can also be achieved with conventional maize 
and without accompanying physiopathological alterations 
in the animals.
Comparison of the haematology and clinical 
biochemistry parameters as well as the relative organ 
weights in control and GMO‑fed rats
The following discussion on differences in the haematol-
ogy and clinical biochemistry parameters as well as in the 
relative organ weights is based on the differences identi-
fied by the SES analyses. After 12 months, the percentage 
of eosinophils was significantly increased in male rats fed 
Table 7  Urinalysis data of female rats fed the control, conventional 2, 11 % GMO or 33 % GMO diet for 3, 6 and 12 months
Glucose, bilirubin, urobilinogen and nitrate were negative in all analysed urine samples











0 0.25 0.75 1.5 0 0.5 1.5 5 0 25 100 500 0 10 25 50 250 5 6 6.5 7 8
Control
 3 10 10 0 0 0 2 3 5 0 9 1 0 0 10 0 0 0 0 2 3 5 0 0
 6 10 10 0 0 0 6 3 1 0 10 0 0 0 10 0 0 0 0 0 7 2 1 0
 12 9 8 1 0 0 2 1 6 0 3 3 3 0 9 0 0 0 0 0 8 1 0 0
Conv. 2
 3 10 9 1 0 0 3 4 3 0 8 2 0 0 10 0 0 0 0 0 5 2 3 0
 6 10 9 0 0 1 4 6 0 0 7 2 0 1 10 0 0 0 0 0 5 2 3 0
 12 10 8 2 0 0 7 1 2 0 7 1 2 0 10 0 0 0 0 2 5 1 2 0
11 % GMO
 3 10 10 0 0 0 3 5 2 0 9 1 0 0 10 0 0 0 0 5 2 3 0 0
 6 10 10 0 0 0 8 0 2 0 9 1 0 0 10 0 0 0 0 1 8 1 0 0
 12 10 7 3 0 0 3 3 4 0 6 1 1 2 9 0 0 0 1 4 4 0 2 0
33 % GMO
 3 10 9 1 0 0 3 3 4 0 9 1 0 0 10 0 0 0 0 0 5 5 0 0
 6 10 9 1 0 0 4 1 5 0 5 2 3 0 9 0 0 0 1 0 7 3 0 0
 12 10 7 1 2 0 3 2 5 0 5 3 1 1 9 0 0 1 0 4 5 1 0 0
Point in time (months) Number of animals Osmolality (mOsm/kg H2O)
Control
 3 10 484.5 ± 120.2
 6 10 432.0 ± 105.6
 12 9 588.6 ± 142.9
Conv. 2
 3 10 402.6 ± 190.9
 6 10 478.9 ± 206.7
 12 10 465.0 ± 219.5
11 % GMO
 3 10 444.1 ± 220.0
 6 10 463.2 ± 137.7
 12 10 604.3 ± 211.8
33 % GMO
 3 10 488.4 ± 274.8
 6 10 540.0 ± 269.8
 12 10 589.9 ± 213.9
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the conventional 2 and 11 % GMO diets, but not in male 
animals fed the 33 % GMO diet when compared to the con-
trol group. At the same sampling time, the percentage of 
eosinophils was significantly decreased in female rats fed 
the conventional 2 and 11 % GMO diets, while in female 
rats fed the 33 % GMO diet the percentage of eosinophils 
significantly increased after 3 months and significantly 
decreased after 6 months, while it was not statistically 
different from that in the control group after 12 months. 
The number of WBC was significantly increased in male 
Table 8  Relative weight of 
the organs (cage mean ± SD) 
of male and female Wistar 
Han RCC rats in the 1-year 
feeding trial with the GM maize 
MON810
1 The organs of 20 (19 in the case of the right adrenal gland), 20, 20 and 19 male rats fed the control, con-
ventional 2, 11 % GMO or 33 % GMO diet, respectively, were evaluated
2 The organs of 19, 20, 19 and 20 female rats fed the control, conventional 2, 11 % GMO or 33 % GMO 
diet, respectively, were evaluated
a Statistically significant difference to control group based on one-way ANOVA, post hoc t test (p < 0.05), 
post hoc Dunnett test
(p < 0.05)
(a) Statistically significant difference to control group (p < 0.05) based on one-way ANOVA and post hoc t 
test, post hoc Dunnett test not significant
b Statistically significant difference to control group (p < 0.05) based on Wilcoxon test
c Statistically significant difference to control group based on 95 % confidence interval of the SES
Male rats Relative organ weights (organ weight/body weight × 100)1
Organ Control Conventional 2 11 % GMO 33 % GMO
Kidney (right) 0.234 ± 0.018 0.233 ± 0.017 0.239 ± 0.016 0.245 ± 0.012
Kidney (left) 0.219 ± 0.015 0.219 ± 0.016 0.228 ± 0.020 0.224 ± 0.016
Spleen 0.182 ± 0.020 0.175 ± 0.009 0.174 ± 0.016 0.186 ± 0.029
Liver 2.370 ± 0.122 2.410 ± 0.174 2.380 ± 0.144 2.466 ± 0.199
Adrenal gland (right) 0.004 ± 0.0003 0.004 ± 0.001 0.004 ± 0.001 0.004 ± 0.001
Adrenal gland (left) 0.004 ± 0.001 0.004 ± 0.001 0.004 ± 0.001 0.004 ± 0.001
Lung 0.247 ± 0.020 0.235 ± 0.022 0.244 ± 0.018 0.251 ± 0.020
Heart 0.207 ± 0.010 0.207 ± 0.009 0.197 ± 0.011 0.209 ± 0.012
Thymus 0.095 ± 0.018 0.091 ± 0.014 0.095 ± 0.019 0.101 ± 0.012
Pancreas 0.124 ± 0.023 0.114 ± 0.015 0.121 ± 0.013 0.129 ± 0.021
Testis (right) 0.370 ± 0.038 0.355 ± 0.072 0.367 ± 0.019 0.374 ± 0.036
Testis (left) 0.366 ± 0.035 0.346 ± 0.067 0.367 ± 0.016 0.373 ± 0.041
Epididymis (right) 0.117 ± 0.013 0.112 ± 0.019 0.115 ± 0.009 0.118 ± 0.011
Epididymis (left) 0.117 ± 0.011 0.112 ± 0.020 0.116 ± 0.007 0.116 ± 0.012
Brain 0.391 ± 0.037 0.383 ± 0.036 0.394 ± 0.023 0.410 ± 0.040
Female rats Relative organ weights (organ weight/body weight × 100)2
Organ Control Conventional 2 11 % GMO 33 % GMO
Kidney (right) 0.280 ± 0.032 0.306 ± 0.027 0.307 ± 0.025 0.300 ± 0.015
Kidney (left) 0.262 ± 0.025 0.278 ± 0.024 0.282 ± 0.030 0.278 ± 0.018b
Spleen 0.227 ± 0.041 0.227 ± 0.036 0.229 ± 0.028 0.226 ± 0.027
Liver 2.559 ± 0.235 2.667 ± 0.268 2.639 ± 0.203 2.583 ± 0.149
Adrenal gland (right) 0.009 ± 0.001 0.009 ± 0.001 0.009 ± 0.001 0.009 ± 0.001
Adrenal gland (left) 0.009 ± 0.002 0.010 ± 0.002 0.010 ± 0.003 0.010 ± 0.002
Lung 0.305 ± 0.027 0.317 ± 0.030 0.326 ± 0.028 0.318 ± 0.024
Heart 0.248 ± 0.021 0.252 ± 0.017 0.259 ± 0.018 0.259 ± 0.012
Thymus 0.119 ± 0.019 0.120 ± 0.013 0.123 ± 0.012 0.137 ± 0.022
Pancreas 0.185 ± 0.024 0.201 ± 0.022 0.184 ± 0.025 0.176 ± 0.023
Uterus 0.177 ± 0.051 0.219 ± 0.046 0.235 ± 0.075 0.203 ± 0.055
Ovary (right) 0.012 ± 0.003 0.009 ± 0.003a,c 0.013 ± 0.003 0.011 ± 0.003
Ovary (left) 0.012 ± 0.003 0.009 ± 0.003 0.012 ± 0.003 0.010 ± 0.001
Brain 0.600 ± 0.052 0.612 ± 0.063 0.646 ± 0.057 0.627 ± 0.052
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Table 9  Gross necropsy observations and histopathological findings in male Wistar Han RCC rats fed the control or 33 % GMO diet for 1 year
Group Animal no. Gross necropsy observations Histopathological findings
Control 41 None No histopathological alterations
42 None No histopathological alterations
43 None Focal interstitial nephritis in the left and right kidney, lym-
phoepithelioid granuloma in the small intestine
44 None No histopathological alterations
45 None No histopathological alterations
46 Red-brown coloured surface on the right side of the 
prostate
No histopathological alterations
47 Thickened area on the frontal bone Bone sample not analysed
48 None Meibomian gland hyperplasia
49 None Focal mononuclear infiltration in the heart
50 None No histopathological alterations
51 Brown coloured, oval-shaped mass of soft consistency in 
adipose tissue surrounding the left epididymis
No histopathological alterations
52 None Focal mononuclear infiltration in the heart, focal chronic 
interstitial prostatitis and lymphatic sinus ectasia
53 None No histopathological alterations
54 Bilateral petechial haemorrhage (site: submandibular 
lymph node)
Focal mononuclear infiltration in the heart, no further histo-
pathological alterations
55 None No histopathological alterations
56 None Tubular dilation and atrophy in the left and right kidney
57 Grey-coloured adipose tissue surrounding the right 
epididymis
No histopathological alterations
58 None No histopathological alterations
59 None Cysts in the pituitary gland
60 None No histopathological alterations
Group Animal no. Gross necropsy observations Histopathological findings
33 % GMO 1 None Focal mononuclear infiltration in the heart
2 Grey-coloured adipose tissue No histopathological alteration of the adipose tissue, 
focal interstitial nephritis in the left and right kidney
3 None No histopathological alterations
4 None No histopathological alterations
5 None No histopathological alterations
6 None No histopathological alterations
7 None Lymphoepithelioid granuloma in the small intestine, 
focal mononuclear infiltration in the heart
8 None Tubular dilation and atrophy in the left and right kidney
9 None Cysts in the pituitary gland
10 None No histopathological alterations
11 None Cortical nodular hyperplasia in the left adrenal gland
12 None Cortical nodular hyperplasia in the right adrenal gland, 
follicular cystic hyperplasia in the thyroid gland and 
lymphatic sinus ectasia
13 None Focal cortical vacuolar degeneration in the right adrenal 
gland
14 None No histopathological alterations
15 None No histopathological alterations
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rats fed the 11 and 33 % GMO diet after 6 months when 
compared to control diet-fed animals. No differences were 
detected in male rats either after 3 and 12 months or in 
female animals throughout the whole feeding trial. Taken 
together, there is no evidence of an event-related effect of 
the GM maize MON810 on the percentage of eosinophils 
in the blood, which is in line with the observation that 
(Cry1Ab-containing) maize MON810 does not induce rel-
evant changes in immune parameters when rats are fed a 
33 % GMO diet for up to 90 days (Tulinska et al., manu-
script in preparation), and on the number of WBC.
In the case of the clinical biochemistry data, a low 
number of parameters were significantly altered when 
the control and the GMO groups were compared. After 
publishing the results of the first two 90-day feeding tri-
als, studies A and B, in the frame of the GRACE project 
(Zeljenková et al. 2014), it was argued in the frame of dis-
cussions with the stakeholders that: (1) the GRACE con-
sortium had dismissed the toxicological relevance of the 
observed lower levels of TP in serum in rats fed the GM 
maize MON810, which could be due to a nephrotic syn-
drome or to an impaired protein synthesis in the liver; (2) 
the GRACE consortium had dismissed the decrease in the 
relative pancreas weight and the increase in the blood GLU 
levels. The results of the present study show that: (1) the 
blood TP levels remained unchanged in male and female 
rats fed the 11 % GMO and 33 % GMO diets for up to 
1 year when compared to the control group; (2) the histo-
pathological analyses of the kidneys and liver of the rats 
fed the 33 % GMO diet revealed no signs of a nephrotic 
syndrome or liver toxicity; (3) the relative pancreas weight 
remained unchanged in male and female rats fed the 11 % 
GMO and 33 % GMO diets for up to 1 year when com-
pared to the control group; and (4) the blood GLU levels in 
male and female rats fed the 11 % GMO and 33 % GMO 
diets for up to 1 year in no case increased when compared 
to the control group. Hence, the conclusions raised in the 
study by Zeljenková et al. (2014) and commented by Stein-
berg (2015) are clearly supported and confirmed by the 
results obtained in the present 1-year feeding trial with the 
GM maize MON810.
Blood AST activity was only decreased in male rats 
fed the conventional 2 diet after 3 months and increased 
in male rats fed the 33 % GMO diet for 6 months, while 
other liver function-related biomarkers such as blood 
ALP and ALT activities as well as blood TP and ALB 
levels remained unchanged in those animals when com-
pared to the corresponding control group. No liver func-
tion-related biomarkers were altered in male rats fed the 
GMO diets for 3 and 12 months and in female rats fed 
the GMO diets for 3, 6 and 12 months. Moreover, no 
histopathological alterations were observed in male and 
female rats fed the GMO diets. Thus, it is concluded that 
the GM maize feeding did not lead to liver toxicity and 
that the above-mentioned AST activity increase was not 
event-related.
The blood GLU level in female rats fed the 33 % GMO 
was significantly lower after 6 months if compared to the 
corresponding control animals, but this was not the case 
after 12 months. The blood GLU levels in male rats fed the 
11 % GMO diet were significantly lower after 12 months, 
while the blood GLU level in male animals fed the 33 % 
GMO diet for 12 months showed no alterations. Based 
on the above-mentioned results, it is concluded that the 
sporadic decrease in blood glucose levels observed in the 
1-year feeding trial with the GM maize MON810 was not 
related to the MON810 event.
The blood CREA level was slightly increased in female 
rats fed the 11 % GMO diet for 12 months, but not in 
female rats fed the 33 % GMO diet for 12 months or in 
male rats fed the 11 % GMO and 33 % GMO diets for up 
to 12 months. In this context, it should be pointed out that 
the increase in the blood CREA level in female rats fed the 
11 % GMO diet for 12 months was not accompanied by 
changes in further kidney-related parameters such as blood 
U and electrolyte levels. Moreover, there was no relevant 
increase in the incidence of histopathological alterations in 
the kidneys of animals fed the 33 % GMO diet if compared 
with the control group. Therefore, it is concluded that the 
feeding of maize MON810 did not lead to kidney toxic-
ity and that the above-mentioned CREA increase was not 
event-related.
Table 9  continued
Group Animal no. Gross necropsy observations Histopathological findings
16 None Focal mononuclear infiltration in the heart
17 None No histopathological alterations
18 None No histopathological alterations
19 None No histopathological alterations
20 None Tubular dilation and atrophy in the left and right kidney
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Table 10  Gross necropsy observations and histopathological findings in female Wistar Han RCC rats fed the control or 33 % GMO diet for 
1 year
Group Animal no. Gross necropsy observations Histopathological findings
Con-
trol
141 None No histopathological alterations
142 None No histopathological alterations
143 Cystic formation in the right ovary Follicular cysts in the right ovary
144 Bilateral petechial haemorrhage (site: submandibular 
lymph node), hyperaemic pituitary gland, maxilla defor-
mation, thickened skin area
Cutaneous papilloma, cystic endometrial hyperplasia
145 Cystic formation in the right ovary Follicular cysts in the right ovary
146 Cystic formation in the left and right ovary Follicular cysts in the left and right ovary
147 Bilateral hyperaemic submandibular lymph node Cysts in the thymus, no further histopathological alterations
148 None Follicular cysts in the left ovary
149 None Tubular dilation and atrophy in the right kidney
150 None No histopathological alterations
151 None Focal interstitial nephritis in the rat kidney
152 None No histopathological alterations
153 Hyperaemic right submandibular lymph node, petechiae on 
the left submandibular lymph node, cystic formation in 
the left and right ovary
Tubular dilation and atrophy in the right kidney, no further 
histopathological alterations
154 Bilateral petechial haemorrhage (submandibular lymph 
node)
No histopathological alterations
155 None No histopathological alterations
156 Diaphragmatic hernia Diaphragm sample not analysed
157 Light brown-coloured mass of adipose tissue on the right 
side of the abdominal cavity
Lipoma
158 Thickened right horn of the uterus Cystic endometrial hyperplasia, focal hyperplasia/zona 
fasciculata in the right adrenal gland
159 Mammary gland abscess, bilateral petechial haemorrhage 
(submandibular lymph node)
Mammary gland comedocarcinoma
160 None No histopathological alterations
Group Animal no. Gross necropsy observations Histopathological findings
33 % GMO 101 Cystic formation in the right ovary Follicular cysts in the right ovary
102 Light brown coloured mass in the epigastrium Lipoma
103 Bilateral petechial haemorrhage (site: subman-
dibular lymph node), atrophy of the left and 
right ovary
Lack of secondary and tertiary follicles in the left and 
right ovary; no further histopathological alterations
104 Hyperaemic, dark coloured submandibular 
lymph node
No histopathological alterations
105 Hyperaemic pituitary gland No histopathological alterations
106 Cystic formation in the left and right ovary Follicular cysts in the left and right ovary
107 Superficially damaged skin surface Skin sample not analysed
108 None No histopathological alterations
109 Cystic formation in the left and right ovary Follicular cysts in the left and right ovary
110 Bilateral hyperaemia in the submandibular 
lymph node, cystic formation in the left and 
right ovary
Follicular cysts in the left and right ovary
111 Bilateral hyperaemia in the submandibular 
lymph node
Endometrial stromal hyperplasia; no further no histo-
pathological alterations
112 Damaged skin surface Focal hyperkeratosis, spongiosis, acanthosis, granulation 
tissue, hypertrophy of the sebaceous glands and follicu-
lar dysplasia (site: skin); follicular cysts in the rat ovary
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The blood P levels were increased in male rats fed the 
11 % GMO and 33 % GMO diets to a similar extent (i.e. 
in a dose-independent manner) after 6 months and slightly 
increased in male rats fed the 11 % GMO (but not the 33 % 
GMO) diet after 12 months when compared to the corre-
sponding control group. The blood Cl level was increased 
in male rats fed the 33 % GMO diet after 3 months, whereas 
after 6 and 12 months no changes in the blood Cl levels of 
male rats were detected. In female rats, the blood P and Cl 
levels were not altered at any point in time of the feeding 
trial. If one takes into account that the above-mentioned 
changes in the blood P and Cl levels were not accompanied 
by changes in kidney-related parameters such as blood U, 
CREA and further electrolyte levels and that there was no 
relevant increase in the incidence of histopathological alter-
ations in the kidneys of animals fed the 33 % GMO diet 
when compared with the control group, it is concluded that 
the feeding of maize MON810 did not lead to kidney toxic-
ity and that the P and Cl increases were not event-related.
The only additional significantly altered clinical bio-
chemistry parameter detected by the classical statistical 
analysis approach was an increase in the AST activity in 
female rats fed the 33 % GMO diet for 12 months. Since all 
other liver function-related biomarkers such as blood ALP 
and ALT activities as well as blood TP and ALB levels 
remained unchanged in female animals when compared to 
the corresponding control group, no liver function-related 
biomarkers were altered in male rats fed the GMO diets 
for 3, 6 and 12 months and no histopathological alterations 
were observed in male and female rats fed the 33 % GMO 
diet, it is concluded that the GM maize feeding did not lead 
to liver toxicity and that the above-mentioned AST activity 
increase in female rats was not event-related.
Necropsy and histopathological findings
The macroscopic examination of all animals at necropsy 
revealed a very limited number of findings in all four 
experimental groups. The histopathological analysis of the 
organs and tissues obtained from all animals of the con-
trol and 33 % GMO group identified a very low number 
of alterations in both groups. Since there were no relevant 
differences in the incidence of histopathological findings 
between these two groups, it is concluded that the altera-
tions were not event-related.
Table 10  continued
Group Animal no. Gross necropsy observations Histopathological findings
113 Bilateral hyperaemia in the submandibular 
lymph node
No histopathological alterations
114 Bilateral hyperaemia in the submandibular 
lymph node
No histopathological alterations
115 None Lymphoepithelioid granuloma in the small intestine
116 Bilateral petechial haemorrhage (site: subman-
dibular lymph node)
Tubular dilation and atrophy in the left kidney, no further 
histopathological alterations
117 Cystic formation in the left ovary Follicular cysts in the left ovary, lymphoepithelioid 
granuloma in the small intestine, cysts in the pituitary 
gland
118 Bilateral petechial haemorrhage (site: subman-
dibular lymph node)
No histopathological alterations
119 None No histopathological alterations
120 None No histopathological alterations
Table 11  Summary of the histopathological findings (except for 
benign and malignant tumours) in male Wistar Han RCC rats fed the 
control or 33 % GMO diet for 1 year
Organ Histological finding Control 33 % GMO
Adrenal gland Focal hyperplasia/zona 
fasciculata
0/20 2/19
Focal cortical vacuolar 
degeneration
0/20 1/19
Heart Mononuclear infiltration 3/20 2/19
Hypophysis Cysts 1/20 1/19
Kidney Focal interstitial nephritis 1/20 1/19
Tubular dilation and 
atrophy
1/20 2/19
Lymph node Lymphatic sinus ectasia 1/20 1/19
Meibomian gland Hyperplasia 1/20 0/19
Prostate Focal chronic interstitial 
prostatitis
1/20 0/19
Small intestine Lymphoepithelioid granu-
loma
1/20 1/19
Thyroid gland Follicular cystic hyper-
plasia
0/20 1/19
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The very low incidence of non-neoplastic and neoplas-
tic lesions in Wistar Han RCC rats is in line with previ-
ous reports (King-Herbert and Thayer 2006; Weber et al. 
2011). Thus, these findings support the use of Wistar Han 
RCC rats in chronic toxicity and carcinogenicity studies. 
One conventional 2-fed female rat developed a pituitary 
haemangioma and one 11 % GMO-fed female rat a yolk 
sac carcinoma, a rare spontaneous neoplasm of germ cell 
origin (Sobis 1987; Nakazawa et al. 1998; Sakamoto et al. 
2011). No malignant tumours were detected in 33 % GMO-
fed rats.
Statistical methods: SES analysis versus classical 
statistical analysis
In the present study paper, the endpoints measured in the 
different experimental groups were compared applying 
both the SES analysis as recommended by EFSA (EFSA 
Scientific Committee 2011) and the classical statistical 
approach, i.e. decision tree-based, as recommended by the 
OECD (OECD 2012). The classical approach (significance 
tests) involved the comparison of the group means for each 
endpoint, i.e. difference tests to identify statistically signifi-
cant group differences (=effect sizes). The SES approach 
estimates are displayed as confidence intervals for the 
(standardized) differences of the means.
The results of the SES approach very closely (by 99 %) 
agree with those of the classical statistical approach, which 
simply asks whether there is an effect. The confidence 
intervals estimated by the SES approach additionally pro-
vide information on the magnitude of any response, i.e. 
how strong the effect is.
In the frame of the present study, all endpoints were 
also analysed by applying a single classical statistical test 
procedure, a one-way ANOVA followed by post hoc t test, 
a one-way ANOVA followed by post hoc Dunnett test and 
the Kruskal–Wallis test followed by the Wilcoxon test. 
The one-way ANOVA followed by post hoc t test detected 
Table 12  Summary of the histopathological findings (except for benign and malignant tumours) in female Wistar Han RCC rats fed the control 
or 33 % GMO diet for 1 year
Organ Histological finding Control 33 % GMO
Adrenal gland Focal proliferation of interstitial cells 0/19 0/20
Endometrium Cystic endometrial hyperplasia 2/19 1/20
Endometrial stromal hyperplasia 0/19 0/20
Hypophysis Cysts 0/19 1/20
Kidney Focal interstitial nephritis 1/19 0/20
Tubular dilation and atrophy 2/19 1/20
Ovary Cysts 4/19 6/20
Proliferation of stromal interstitial cells 0/19 0/20
Skin Focal hyperkeratosis, spongiosis, acanthosis, granulation tissue,  
hypertrophy of the sebaceous glands and follicular dysplasia
0/19 1/20
Small intestine Lymphoepithelioid granuloma 0/19 2/20
Thymus Cysts 1/19 0/20
Table 13  Benign and malignant tumours observed in rats fed the 
control or 33 % GMO diet in the present study
Female rats Control 33 % GMO
Benign tumours
 Lipoma 1/19 1/20
 Cutaneous papilloma 1/19 0/20
Malignant tumours
 Mammary gland comedocarcinoma 1/20 0/20
0




























Fig. 7  Calculated dose of fumonisins in rats fed the control diet in 
the first 13 weeks of the 1-year feeding trial. For the calculations, 
the amount of the fumonisins B1, B2 and B3 were added up. The red 
line represents the lowest no observed adverse effect level (NOAEL) 
value reported for fumonisin B1 in rats, i.e. an NOAEL value of 
0.2 mg/kg body weight/day for kidney toxicity in a subchronic toxic-
ity study (Voss et al. 1995)
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the highest total number of significant differences, 
i.e. about twice as much as the decision tree-based clas-
sical approach (39 vs. 19). The ANOVA followed by post 
hoc Dunnett test found a low total number of significant 
differences, i.e. about half as much as the decision tree-
based classical approach (12 vs. 19). The Kruskal–Wallis 
test followed by the Wilcoxon test found the lowest total 
number of significant differences, i.e. about half as much 
as the decision tree-based classical approach (11 vs. 19). 
This is due to:
•	 the (non-)appropriateness of an applied statistical 
method to an endpoint (the assumptions underlying the 
specific test are (not) met);
•	 the different philosophies behind the statistical methods: 
ANOVA with post hoc t test /Dunnett test is based on 
the original values, whereas the nonparametric Kruskal–
Wallis test followed by the Wilcoxon test is not based 
on the original values itself, but on their ranks;
•	 the different approaches to control the probability of 
type I errors (in contrast to the t test, the Dunnett test 
controls the experimentwise error).
Taken together, the t test is a very conservative and 
cautious approach that detects a rather high number of 
significant differences, while the nonparametric test is an 
approach that detects a rather low number of significant dif-
ferences. In contrast, the decision tree-based classical sta-
tistical approach and the SES approach provide a balanced 
and reliable analysis of the results.
At the present time, the SES approach is unfamiliar to 
most toxicologists. The standardization allows to compare 
all endpoints at a glance and helps in evaluating the toxi-
cological relevance of the results obtained. In this context, 
the use of the SES approach provides an added value to the 
classical statistical analyses applied in feeding trials with 
whole food/feed, as shown in the present study.
The advantages of (standardized) effect size estimations 
have comprehensively been described and discussed by 
Ellis (2010), Festing (2014) and Schmidt et al. (2015b) and 
are summarized as follows:
•	 Assessing the magnitude of an effect instead of just its 
statistical significance supports the interpretation of its 
toxicological relevance.
•	 References to historical data are easier to interpret hav-
ing the variation of effect sizes displayed in form of 
confidence intervals.
•	 For significance tests, graphical methods are not widely 
available, while for effect sizes a range of graphical 
methods are applicable.
•	 By making use of standardization, all endpoints of a 
feeding trial can be expressed in the same units and dis-
played in a single graph.
In conclusion, the 1-year feeding trial performed with a 
MON810 maize variety in the frame of the GRACE project 
shows that the MON810 maize at a level of up to 33 % in the 
diet does not lead to toxicologically relevant effects in male 
and female Wistar Han RCC rats after a 1-year exposure, 
independently of the applied statistical analysis approach.
Suitability of rat feeding studies for the health risk 
assessment of GM food and feed
There is an ongoing discussion in the EU whether untargeted 
feeding trials in rodents with whole GM food/feed should 
become a mandatory testing procedure to investigate any 
unanticipated effect of GM food/feed in the frame of the risk 
assessment process. In this context, one of the main objec-
tives of the GRACE project was to test GM maize MON810 
varieties in subchronic (Zeljenková et al. 2014; Schmidt et al. 
2016) and chronic rat feeding trials (the present study) and, 
based on the obtained results, to evaluate whether such feed-
ing trials are suited to reveal such unintended effects elic-
ited by the genetic modification by an “untargeted” testing, 
i.e. without a triggering assumption resulting from preced-
ing investigations on a potential effect and, hence, without a 
specified cause-effect hypothesis. The data did not provide 
any indication that the performance of the rat feeding studies 
with whole food/feed would provide additional information 
on the safety of the GM maize MON810 when compared to 
the compositional comparison of the GM line and its closest 
conventional comparator. Moreover, the data generated by 
the GRACE project showed that non-targeted feeding stud-
ies may generate outcomes at the level of the variability of 
the laboratory performing the studies, i.e. generating signifi-
cant differences in a random manner, and suggest that animal 
feeding trials may lack the sensitivity needed to detect unin-
tended effects elicited by the genetic modification.
Table 14  Comparison of the mean body weight variation in the 
case of male and female rats fed the control, conventional 2, 11 % 
GMO or 33 % GMO diet for 90 days in the GRACE project study A 
(Zeljenková et al. 2014) and in the present study
Conventional 2 
versus control  
(% mean body  
weight  
variation)
11 % GMO  
versus control  
(% mean body 
weight  
variation)
33& GMO  
versus control  




 Males −4.52 −0.98 −0.50
 Females −3.93 −3.38 −3.92
Present study
 Males −0.79 1.38 −5.56
 Females −1.54 −3.26 −4.65
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The need to provide nutritionally balanced diets lim-
its the maximum inclusion rate of the plant material to 
be tested and, thus, restricts the exposure level of the ani-
mals to the respective GM food/feed. In this context, the 
expected magnitude of a distinctly identified potential 
effect should be included into the test hypothesis and trig-
ger the decision whether a feeding study should/could 
be performed to achieve a clear test response. The study 
design should follow the test hypothesis and should provide 
clear test results. A standard approach may not be the pri-
mary choice to achieve this objective.
Taken together, the GRACE data support the scientific 
reasoning that only in case that a trigger has been identified 
in the course of the initial molecular, compositional, pheno-
typic and/or agronomic analyses, feeding trials with whole 
food/feed may provide an added scientific value for the 
risk assessment of GM crops (EFSA Scientific Committee 
2011). If safety concerns are raised during the molecular, 
compositional, phenotypic and/or agronomic analyses, a 
feeding trial might be considered, provided that a targeted 
hypothesis can be developed to tailor the study design to 
the posed safety concern.
In line with the GRACE transparency policy, any inter-
ested person will have access to the raw data obtained in the 
frame of GRACE, including the clinical, ophthalmological, 
haematology, clinical biochemistry, organ weight, necropsy 
and histopathology data presented in this study through 
an internet portal named CADIMA (Central Access Data-
base for Impact Assessment of Crop Genetic Improvement 
Technologies; www.cadima.info).
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